This learning series is accredited for AMA PRA Category 1 Credit™  from April 15, 2025 until April 15, 2027.

Watch the recording and complete your evaluation here.

In this webinar, you will hear from oncologists and primary care providers outlining important updates in regards to breast, gynecological, colon, and prostate cancer. Part 4 of 5 aims to bring non-genetic providers up to speed on guidelines and ways you can implement them in your practice.

Educational Objectives

Upon completion of this educational activity, participants should be able to:

• Apply updates in personalized treatment related to breast cancer and genetics.
• Explain updates in personalized treatment related to colon cancer and genetics.
• Integrate updates in personalized treatment related to gynecologic cancer and genetics.
• Use updates in personalized treatment related to prostate cancer and genetics.

Target Audience

This activity is designed to educate practitioners, medical regulatory staff, and the public.

	Bruce Montgomery, MD Bruce Montgomery, MD is professor of Medicine, Oncology and Urology at the University of Washington and affiliate member of Fred Hutch Cancer Center. He is board certified in Oncology and is a Seattle Met and Seattle Magazine Top Doctor.  Dr. Montgomery earned his medical degree at Duke, did his residency in internal medicine at Brigham and Women's Hospital and fellowship in Oncology at Fred Hutch Cancer Center. Dr. Montgomery divides his time between seeing patients and doing research at Fred Hutch and the VA Puget Sound.
	Marianne Dubard-Gault, MD, MS Dr. Dubard-Gault earned her medical degree and masters in biochemistry from the Université de Médecine de Lyon, then completed a combined medicine and research residency, at the Université de Médecine de Bordeaux, France. She is now board certified in internal medicine and in genetics after training at the University of Pennsylvania, in Philadelphia, PA, and Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, NY. She is currently the medical director of Cancer Genetics & High-risk Services at the Swedish Cancer Institute and a clinician scientist at the Paul G. Allen Research Center in Seattle, WA.  Her main research interests are 1) to help expand access to genetics and high-risk services for patients with a hereditary cancer syndrome, 2) to improve strategies for cancer screening, risk reduction, and early cancer detection, and 3) to better understand how genetic information influences patients’ decision-making about health care and life choices.
	Nina Tan, MD Dr. Nina Tan is a primary care internist and breast health physician at Fred Hutch and University of Washington. She received her medical degree and completed her residency in internal medicine at the University of Washington School of Medicine with a focus on primary care and women's health. Dr. Tan sees patients who are at high risk for breast cancer or who have benign breast disease at the UW and Fred Hutch Breast Health Clinics, including the Fred Hutch Breast and Ovarian Cancer Prevention clinic.
	Katie Stoll, MS, CGC - Moderator Katie is a licensed genetic counselor and executive director of Genetic Support Foundation. She earned her master’s degree in genetic counseling degree from Brandeis University with her clinical internship at Dana-Farber Cancer Institute. She has worked in a variety of clinical settings, seeing patients for multiple specialties for more than 20 years. In addition to providing direct patient care, Katie leads work at Genetic Support Foundation to develop resources and build programs to expand the availability of up-to-date information about genetics, and to increase access to genetic counseling services.

Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Federation of State Medical Boards, the Washington Medical Commission, and the Washington State Department of Health. The Federation of State Medical Boards is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The Federation of State Medical Boards designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Course Director

Pamela Kohlmeier MD, JD, FACEP
Washington Medical Commission

Commercial Support

This learning activity is not funded by any commercial entity.

Disclosure Declaration

As an organization accredited by the ACCME, the Federation of State Medical Boards (FSMB) requires that the content of CME activities and related materials provide balance, independence, objectivity, and scientific rigor. All faculty, planners, and others in a position to control continuing medical education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Faculty (authors, presenters, speakers and planners) are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or other options available when utilizing trade names to ensure impartiality.

Faculty members are asked to disclose all financial relationships they have had in the past 24 months with ineligible companies regardless of the potential relevance of each relationship to the education and of the amount. The FSMB has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity. The intent of this policy is to identify potential conflicts of interest so participants can form their own judgments with full disclosure of the facts. Participants will be asked to evaluate whether the speaker’s outside interests reflect a possible bias in the planning or presentation of the activity. 

Bruce Montgomery, MD, has received grant/research support from Janssen, Immune Biosciences, and Bayer, and is on the Plexux CME speaker's bureau. All relevant financial relationships have been mitigated.                                                               

None of the other speakers or planners for this activity have relevant financial relationships to disclose with ineligible companies.

Disclosure of Unlabeled Uses

This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product, or consult the Physicians’ Desk Reference.

Faculty and Staff Disclosures

No speaker or persons in control of content reported intent to reference unlabeled/unapproved uses of drugs or products.